Advances in biomarkers of resistance to KRAS mutation-targeted inhibitors
Abstract KRAS mutations represent the most common driver genetic alterations in multiple malignant tumors, particularly exerting well-defined oncogenic driver roles in non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. The recent success of KRAS G12C mutation-specif...
Αποθηκεύτηκε σε:
| Κύριοι συγγραφείς: | , , , |
|---|---|
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Springer
2025-10-01
|
| Σειρά: | Discover Oncology |
| Θέματα: | |
| Διαθέσιμο Online: | https://doi.org/10.1007/s12672-025-03569-x |
| Ετικέτες: |
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|